<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="53229">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02413229</url>
  </required_header>
  <id_info>
    <org_study_id>DSXS 1411</org_study_id>
    <nct_id>NCT02413229</nct_id>
  </id_info>
  <brief_title>A Randomized Double Blind Vehicle Controlled Dose Ranging Parallel Design Multiple Site Clinical Study</brief_title>
  <official_title>A Randomized Double Blind Vehicle Controlled Dose Ranging Multiple Site Phase 2 Clinical Study to Evaluate the Efficacy and Safety of DSXS in Patients With Moderate to Severe Scalp Psoriasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Taro Pharmaceuticals USA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Taro Pharmaceuticals USA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objectives of this study are to evaluate the therapeutic efficacy and safety of DSXS and
      a Placebo in patients with moderate to severe scalp psoriasis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This randomized, double-blind, vehicle-controlled, dose-ranging, parallel-group multi-site
      study is designed to evaluate the therapeutic efficacy and safety of the investigational
      product, DSXS, for the treatment of moderate to severe scalp psoriasis at different
      application times up to 30 minutes.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2015</start_date>
  <completion_date type="Actual">January 2016</completion_date>
  <primary_completion_date type="Actual">January 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The proportion of patients in each treatment group that have clinical success at Day 28, which is defined by a Investigator's Global Assessment score of 0 or 1.</measure>
    <time_frame>Day 28</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">151</enrollment>
  <condition>Plaque Psoriasis</condition>
  <arm_group>
    <arm_group_label>DSXS1411</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DSXS applied once a day for a total of 28 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (vehicle) applied once a day for a total of 28 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DSXS1411</intervention_name>
    <description>DSXS (Taro Pharmaceuticals Inc.)</description>
    <arm_group_label>DSXS1411</arm_group_label>
    <other_name>Active</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo (vehicle) (Taro Pharmaceuticals Inc.)</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>vehicle</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or non-pregnant, non-lactating females age 12 and older.

          -  Clinical diagnosis of moderate to severe scalp psoriasis, defined by a Investigator's
             Global Assessment score of at least 3 at screening.

        Exclusion Criteria:

          -  Under 12 years of age.

          -  Patients whose scalp and/or non-scalp psoriasis necessitates systemic or other
             concomitant topical therapies during the study.

          -  Has a scalp skin condition that would interfere with the diagnosis or assessment of
             plaque psoriasis of the scalp.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Natalie Yantovskiy</last_name>
    <role>Study Director</role>
    <affiliation>Taro Pharmaceuticals USA, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Taro Pharmaceuticals USA, Inc.</name>
      <address>
        <city>Hawthorne</city>
        <state>New York</state>
        <zip>10532</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <lastchanged_date>October 8, 2016</lastchanged_date>
  <firstreceived_date>April 6, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
